Protocol for a Randomised Phase II Study of the Stanford V regimen compared with ABVD for the treatment of Advanced Hodgkin's Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN64141244

Enrollment

700

Registered

2002-08-19

Start date

2001-01-01

Completion date

Unknown

Last updated

2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (Hodgkin's) Cancer Hodgkin's disease

Interventions

STANFORD V regimen: Chemotherapy with mustine, doxorubicin, vinblastine, prednisolone, vincristine, bleomycin and etoposide ABVD Regimen: Chemotherapy with doxorubicin, bleomycin, vinblastine and da

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed Hodgkin's disease 2. Clinical stage IIB, IIIA, IIIB or IV 3. Aged 18 - 60 years 4. No previous history of malignancy, except for basal cell or squamous cell carcinoma of the skin 5. Normal values for Full Blood Count (FBC), hepatic and renal function, unless directly attributable to involvement by Hodgkin's disease 6. Written informed consent 7. All patients must be assessed by the treating haematologist/medical oncologist and radiation oncologist TOGETHER prior to study entry. This is an absolute requirement for the study eligibility

Exclusion criteria

Exclusion criteria: 1. Previous therapy for Hodgkin?s disease 2. Clinical evidence of infection with the Human Immunodeficiency Virus (HIV) 3. Pre-existing cardiac or pulmonary disease

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026